Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll
作者： S. Schwander , M. Dietrich , M. Opravil , R. Lüthy , D. G. Hanson
DOI: 10.1007/BF01739010
关键词:
摘要: In order to evaluate tolerance, toxicity, andin vivo antigenicity, 29 HIV-1-infected patients (eight with ARC and 21 AIDS) were vaccinated a synthetic peptide derived from the gp41 transmembrane protein of HIV-1. This had been coupled 2.4 dinitrophenyl-Ficoll (F46), T-cell independent adjuvant. The received single intradeltoid injection either 0.1 or 0.3 mg F46. Five individuals AIDS boostered, four them twice. Anti-F46 antibody titers measured before vaccination, on days 7, 14, 21, 28, 90, 180 270 after vaccination. rose at least twofold over prestudy values in 10/21 1/8 once during observation period. overall response, however, consisted only weak production that was dose patient characteristics. No signs toxicity clinical progression related vaccination observed this phase I/II trial therapeutic vaccine.
springer.com
sci-hub.se 参考文章(38)
Barry S. Stein, Edgar G. Engleman, Mechanism of HIV-1 Entry into CD4+ T Cells Advances in Experimental Medicine and Biology. ,vol. 300, pp. 71- 96 ,(1991) , 10.1007/978-1-4684-5976-0_6
D Gray, E C Gordon-Smith, A E Hayes, P L Amlot, J H Humphrey, Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporine. Clinical and Experimental Immunology. ,vol. 64, pp. 125- ,(1986)
T.C. Chanh, G.R. Dreesman, P. Kanda, G.P. Linette, J.T. Sparrow, D.D. Ho, R.C. Kennedy, Induction of anti-HIV neutralizing antibodies by synthetic peptides. The EMBO Journal. ,vol. 5, pp. 3065- 3071 ,(1986) , 10.1002/J.1460-2075.1986.TB04607.X
P.L Amlot, A.E Hayes, Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for post-splenectomy infections. The Lancet. ,vol. 325, pp. 1008- 1011 ,(1985) , 10.1016/S0140-6736(85)91613-7
F Chiodi, J Albert, T Mathiesen, E Norrby, B Wahren, E Parks, IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection. Journal of Immunology. ,vol. 142, pp. 3809- 3814 ,(1989)
Robert Brasseur, Martine Delchambre, Arsène Burny, Marie Horth, Françoise Bex, Marinee Chuah Lay Khim, Eric Verdin, Human immunodeficiency virus cell entry: New insights into the fusion mechanism Journal of Acquired Immune Deficiency Syndromes. ,vol. 1, pp. 579- 582 ,(1988)
Daniel Zagury, Jacky Bernard, Remi Cheynier, Isabelle Desportes, Regine Leonard, Michelle Fouchard, Brigitte Reveil, Daniele Ittele, Zirimwabagangabo Lurhuma, Kalumbu Mbayo, Justin Wane, Jean-Jacques Salaun, Bernard Goussard, Loic Dechazal, Arsene Burny, Peter Nara, Robert C Gallo, A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS Nature. ,vol. 332, pp. 728- 731 ,(1988) , 10.1038/332728A0
Elaine Kinney Thomas, Jonathan N. Weber, Jan McClure, Paul R. Clapham, Mitra C. Singhal, M. Kathleen Shriver, Robin A. Weiss, Neutralizing monoclonal antibodies to the AIDS virus. AIDS. ,vol. 2, pp. 25- 29 ,(1988) , 10.1097/00002030-198802000-00004
Robert R Redfield, Deborah L Birx, Nzeera Ketter, Edmund Tramont, Victoria Polonis, Charles Davis, John F Brundage, Gale Smith, Steven Johnson, Arnold Fowler, Thomas Wierzba, Avigdor Shafferman, Franklin Volvovitz, Charles Oster, Donald S Burke, Military Medical Consortium for Applied Retroviral Research, A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus Infection New England Journal of Medicine. ,vol. 324, pp. 1677- 1684 ,(1991) , 10.1056/NEJM199106133242401
M Kowalski, J Potz, L Basiripour, T Dorfman, W. Goh, E Terwilliger, A Dayton, C Rosen, W Haseltine, J Sodroski, Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1 Science. ,vol. 237, pp. 1351- 1355 ,(1987) , 10.1126/SCIENCE.3629244